Theratechnologies Reports First Quarter 2021 Financial Results And Recent Business Highlights

Montreal, Canada – April 14, 2021 – Theratechnologies Inc. (Theratechnologies, or Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business highlights and financial results for the first quarter ended February 28, 2021 (Q1 Fiscal 2021). “Theratechnologies is at a unique point in its evolution, …Lire la suite

Theratechnologies To Present At The Bloom Burton & Co. Healthcare Investor Conference

Montreal, Canada – April 12, 2021 – Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Paul Levesque, President and Chief Executive Officer, will present at the Bloom Burton & Co. Healthcare Investor Conference on Wednesday, April 21, 2021 at 10:30 a.m. …Lire la suite

Theratechnologies Presents New In Vivo Pre-Clinical Data At AACR Demonstrating Significant Anti-Tumor Activity Of TH1902 In All Studied Cancer Types

TH1902 anti-tumor post-treatment effect persists longer than with docetaxel alone  Montreal, Canada – April 10, 2021 – Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that new in vivo preclinical data were presented at the 2021 Annual Meeting of the American Association …Lire la suite

Theratechnologies To Announce Financial Results For Its First Quarter Fiscal 2021

Montreal, Canada – April 1, 2021 – Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies announced, today that it will report its financial results for the first quarter of fiscal 2021 ended February 28, 2021 on Wednesday, April 14, 2021.   A conference call …Lire la suite

Theratechnologies Announces Two Strategic Hires To Support Its Commercial And Pipeline Assets

Montreal, Canada – March 29, 2021 – Theratechnologies Inc. (Theratechnologies, or the Company (on a consolidated basis)) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce the addition of two new senior resources to support the growth and development of its commercial and pipeline …Lire la suite

Theratechnologies Announces First Patient Dosed In Phase 1 Clinical Trial Of TH1902 For Sortilin Positive Solid Tumors

Montreal, Canada – March 24, 2021 – Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that the first patient received a dose of TH1902, its lead peptide-drug conjugate (PDC) for the treatment of sortilin positive (SORT1+) solid tumors. “This is …Lire la suite

Theratechnologies Announces New Data Demonstrating Tesamorelin’s Positive Effect On Immune Response Linked To Liver Inflammation

Data presented at ENDO 2021  Montreal, Canada – March 20, 2021 – Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that new data, demonstrating the positive effect of tesamorelin on the circulation of immune activation markers associated with liver inflammation, …Lire la suite

Theratechnologies Announces Two E-Posters On TH1902 To Be Presented At American Association For Cancer Research (AACR) Annual Meeting 2021

Montreal, Canada – March 10, 2021 – Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that new positive pre-clinical data on TH1902, its lead peptide-drug conjugate (PDC) for the treatment of sortilin positive (SORT1+) solid tumors, will be presented in …Lire la suite

Theratechnologies To Present At The H.C. Wainwright Global Life Sciences Conference

Montreal, Canada – February 25, 2021 – Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Paul Levesque, President and Chief Executive Officer, will present at the H.C. Wainwright Global Life Sciences Conference being held virtually March 9 – 10, 2021. The …Lire la suite

Theratechnologies Announces Fourth-Quarter And Fiscal-Year 2020 Financial Results

Record Q4 and FY2020 revenues of $19.1 million and $66.1 million, respectively Montreal, Canada – February 25, 2021 – Theratechnologies Inc. (Theratechnologies, or Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced its financial results for the fourth quarter and its fiscal year ended November …Lire la suite